Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (301-310 of 335) with videos related to

Pageof 34
Sort By:
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Cancer|April 13, 2018
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failureSonali M Smith, James Godfrey, Kwang Woo Ahn, et al.
Transplantation and Cellular Therapy|June 24, 2026
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell LymphomaNausheen Ahmed, Alaa Ali, Soyoung Kim, et al.
Blood Advances|January 13, 2026
Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC StudyMarta Peña, Giulia Losi, Víctor Navarro, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Blood Advances|September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in EuropeElise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 29, 2023
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registryAnahita Mostaghim, Samuel Minkove, Juan Aguilar-Company, et al.
Pageof 34

Showing results (301-310 of 335) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.
Blood|April 24, 2020
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myelomaCristina Perez, Cirino Botta, Aintzane Zabaleta, et al.
Cancer|April 13, 2018
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failureSonali M Smith, James Godfrey, Kwang Woo Ahn, et al.
Transplantation and Cellular Therapy|June 24, 2026
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell LymphomaNausheen Ahmed, Alaa Ali, Soyoung Kim, et al.
Blood Advances|January 13, 2026
Allogeneic HCT as Consolidation in B-cell Lymphomas After Exposure to Bispecific Antibodies: A GETH-TC StudyMarta Peña, Giulia Losi, Víctor Navarro, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Blood Advances|September 24, 2025
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in EuropeElise R A Pennings, Anne M Spanjaart, Frederick W Thielen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2019
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 29, 2023
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registryAnahita Mostaghim, Samuel Minkove, Juan Aguilar-Company, et al.
Pageof 34